Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomised, double blind, active-controlled study.

CONCLUSION: Rosuvastatin 5mg demonstrated non-inferiority and rosuvastatin 10mg demonstrated superiority to atorvastatin 10mg for lowering LDL-C in high risk Chinese patients with dyslipidaemia, which was maintained through the open-label phase. PMID: 28836458 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research